Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
Joao V. Alessi, Biagio Ricciuti, Liam F. Spurr, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 7, pp. 1176-1187
Closed Access | Times Cited: 96

Showing 1-25 of 96 citing articles:

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Marcelo V. Negrão, Haniel A. Araújo, Giuseppe Lamberti, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1556-1571
Open Access | Times Cited: 107
KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
Chengming Liu, Sufei Zheng, Zhanyu Wang, et al.
Cancer Communications (2022) Vol. 42, Iss. 9, pp. 828-847
Open Access | Times Cited: 83
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Joao V. Alessi, Arielle Elkrief, Biagio Ricciuti, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 6, pp. 731-743
Open Access | Times Cited: 54
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer
Biagio Ricciuti, Giuseppe Lamberti, Sreekar Reddy Puchala, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 11, pp. 1311-1321
Open Access | Times Cited: 46
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 27
Recent updates in thoracic SMARCA4-deficient undifferentiated tumor
Aruna Nambirajan, Deepali Jain
Seminars in Diagnostic Pathology (2021) Vol. 38, Iss. 5, pp. 83-89
Closed Access | Times Cited: 63
Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer
Lynette M. Sholl
Modern Pathology (2021) Vol. 35, pp. 66-74
Open Access | Times Cited: 59
STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
Elvire Pons‐Tostivint, Alexandre Lugat, Jean-François Fontenau, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 3129-3129
Open Access | Times Cited: 57
SMARCA4: Current status and future perspectives in non-small-cell lung cancer
Yumeng Tian, Lu Xu, Xin Li, et al.
Cancer Letters (2022) Vol. 554, pp. 216022-216022
Open Access | Times Cited: 53
Fusion‐positive non‐small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications
Daniel Kazdal, Véronique Hofman, Petros Christopoulos, et al.
Genes Chromosomes and Cancer (2022) Vol. 61, Iss. 5, pp. 244-260
Closed Access | Times Cited: 47
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities
Xinan Wang, Giuseppe Lamberti, Alessandro Di Federico, et al.
Annals of Oncology (2024) Vol. 35, Iss. 6, pp. 508-522
Closed Access | Times Cited: 15
Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go
Vito Longo, Annamaria Catino, Michele Montrone, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3237-3237
Open Access | Times Cited: 10
Longitudinal genomic profiling using liquid biopsies in metastatic nonsquamous NSCLC following first line immunotherapy
Haolun Ding, Min Yuan, Yaning Yang, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access | Times Cited: 1
SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils
Yoan Velut, Elise Decroix, Hélène Blons, et al.
Lung Cancer (2022) Vol. 169, pp. 13-21
Open Access | Times Cited: 29
Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor
Ying Lin, Bo Yu, Haifeng Sun, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 11, pp. 8663-8671
Open Access | Times Cited: 18
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
Joao V. Alessi, Biagio Ricciuti, Xinan Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 17
Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment
Apoorvi Chaudhri, Gregory Lizée, Patrick Hwu, et al.
Cancer Research (2024) Vol. 84, Iss. 7, pp. 965-976
Closed Access | Times Cited: 8
Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods
Mengting Shi, Lanlan Pang, Huaqiang Zhou, et al.
Lung Cancer (2024) Vol. 192, pp. 107818-107818
Closed Access | Times Cited: 7
First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial
Huizi Sha, Fan Tong, Jiayao Ni, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 7
Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients
Ting Mei, Ting Wang, Qinghua Zhou
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients
Subasri Armon, Paul Hofman, Marius Ilié
Cells (2021) Vol. 10, Iss. 8, pp. 1920-1920
Open Access | Times Cited: 36
Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
Mo Shen, Rongbin Qi, Justin Ren, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 24
KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions
Nastaran Karimi, Seyed Javad Moghaddam
Cells (2023) Vol. 12, Iss. 5, pp. 749-749
Open Access | Times Cited: 14
SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases
Yue Li, Xinhua Yang, Weijie Zhu, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 22
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
Elona Cekani, Samantha Epistolio, Giulia Dazio, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4103-4103
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top